Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry
Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry

Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry

Rheumatology (Oxford). 2025 Nov 19:keaf613. doi: 10.1093/rheumatology/keaf613. Online ahead of print.

ABSTRACT

OBJECTIVES: The progression of Behçet’s disease (BD) from a mucocutaneous-limited form to major organ involvement (MOI) represents a significant challenge. This study aims to identify patients without MOI at BD onset who are at increased risk of developing MOI in later stages.

METHODS: Patients’ data were drawn from the International AutoInflammatory Disease Alliance (AIDA) Network registry dedicated to BD.

RESULTS: A total of 328 patients with exclusively mucocutaneous manifestations at BD onset were enrolled. Of these, 82 patients (25%) developed MOI over the entire follow-up period. Patients with minor oral aphthosis and no major oral aphthosis exhibited a reduced risk of developing MOI, with an odds ratio (OR) of 0.41 (95% confidence interval [95%CI]: 0.22-0.79, p = 0.008). Conversely, patients with both major and minor oral aphthosis had a significantly higher risk of developing MOI, with an OR of 12.76 (95%CI: 1.44-113, p = 0.02). Moreover, the development of MOI was associated with major oral aphthosis plus genital aphthosis (OR: 2.49, 95%CI: 1.1-5.6, p = 0.03), major oral aphthosis plus pseudofolliculitis (OR: 2.9, 95%CI: 1.15-7.4, p = 0.02), and major oral aphthosis plus both genital aphthosis and pseudofolliculitis (OR: 3.73, 95%CI: 1.22-11.4, p = 0.02). A positive family history for BD was associated with MOI (OR: 2.85, 95%CI: 1.08-7.58, p = 0.03).

CONCLUSION: A positive family history and the presence of major oral aphthosis combined with minor oral aphthosis, genital aphthosis or pseudofolliculitis are associated with MOI development in patients with mucocutaneous BD at onset.

PMID:41259668 | DOI:10.1093/rheumatology/keaf613